

Oral administration of S 78454 in combination with cisplatin in patients with advanced non-keratinising nasopharyngeal carcinoma

Submission date 19/04/2012	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 08/06/2012	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 18/04/2018	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration and not expected to be available in the future

Contact information

Type(s)

Scientific

Contact name

Dr Boon Cher Goh

Contact details

National University Cancer Institute
Department of Haematology - Oncology
5 Lower Kent Ridge Road
Main Building 1, Level 3
-
Singapore
119074

Additional identifiers

Protocol serial number

CL1-78454-009

Study information

Scientific Title

Phase I dose escalation study of oral administration of Pan-Histone Deacetylase (HDAC) inhibitor S 78454 given in combination with a fixed dose infusion of cisplatin in patients with advanced non-keratinising nasopharyngeal carcinoma.

Study objectives

Establish the safety and tolerability of S 78454 given in combination with a fixed dose infusion of cisplatin in patients with advanced non-keratinising nasopharyngeal carcinoma in terms of the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs), and establish the recommended Phase II dose (RP2D).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval was obtained before recruitment of the first participants

Study design

Multicentre international non-randomised non-comparative open-label phase I study

Primary study design

Interventional

Study type(s)

Screening

Health condition(s) or problem(s) studied

Advanced non-keratinising nasopharyngeal carcinoma

Interventions

S 78454 capsules 80 mg twice a day (b.i.d.) to 140mg b.i.d.

Cisplatin / 1 infusion per cycle / 75mg/m² maximum

1. At least 2 cycles of combination treatment.
2. Cisplatin limited to 6 cycles
3. S78454 as long as the disease does not progress and treatment sufficiently tolerated or consent withdrawal

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

Cisplatin

Primary outcome(s)

1. MTD and DLTs of oral S 78454 capsules with a fixed dose infusion of cisplatin
2. Establish the recommended phase II dose

Key secondary outcome(s)

1. Safety profile (adverse events, laboratory tests, physical exam, ECOG, vital signs, ECG, clinical neurological examination, audiometric tests)
2. To determine pharmacokinetic (PK) profile
3. Measure Tumour response according to revised Response Evaluation Criteria In Solid Tumors (RECIST)_ and plasma Epstein-Barr Virus (EBV) DNA levels

Completion date

30/11/2013

Eligibility

Key inclusion criteria

1. Male or female patients aged ≥ 21 (Singapore) ≥ 20 (Taiwan)
2. Histologically documented, measurable or evaluable advanced non-keratinising nasopharyngeal carcinoma, that has relapsed or is refractory to conventional, standard forms of therapy.
3. Ability to swallow oral capsule(s) without difficulty
4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
5. Estimated life expectancy > 12 weeks
6. Adequate haematological, renal and hepatic functions-Serum albumin 30 g/L
7. Written informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Pregnant or breastfeeding women, women of childbearing potential or men without effective contraception
2. Involvement in another clinical trial at the same time or within 4 weeks prior to inclusion, or patient already enrolled in the study
3. Major surgery within previous 4 weeks
4. Chemotherapy within previous 3 weeks (6 weeks in case of nitroso-ureas)
5. Biologic/target therapy or immunologic agents within previous 3 weeks
6. Radiotherapy within previous 4 weeks (except for palliative radiotherapy at localised lesions)
7. Abnormal thyroid function (defined as thyroid-stimulating hormone or free T4) except for patients with hypothyroidism diagnosed prior to study entry and stable on thyroid replacement
8. Concurrent therapeutic anticoagulation by anti-vitamin K (AVK)
9. Uncontrolled diabetes mellitus
10. Concomitant uncontrolled infection or severe systemic disease
11. Symptomatic or progressive brain metastasis

12. Patients with pre-existing gastrointestinal disorders
13. Patient with impaired cardiac function
14. Prior exposure to any Histone deacetylase inhibitors (HDACi)
15. Known organ dysfunction
16. Peripheral neuropathy > grade 1
17. Hearing impairment/tinnitus > grade 2
18. Known hypersensitivity to cisplatin

Date of first enrolment

01/03/2012

Date of final enrolment

30/11/2013

Locations

Countries of recruitment

Singapore

Taiwan

Study participating centre

National University Cancer Institute

-

Singapore

119074

Sponsor information

Organisation

Institut de Recherches Internationales Servier (France)

ROR

<https://ror.org/034e7c066>

Funder(s)

Funder type

Industry

Funder Name

Institut de Recherches Internationales Servier (France)

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from <https://clinicaltrials.servier.com> if a Marketing Authorisation has been granted after 1st January 2014.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results				No	No